Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- CORPORATE ROUNDUP NEWS IN BRIEF
April 2, 2001
- AIN PHARMACIEZ Issues Membership Cards
April 2, 2001
- 18.6% of Inpatients Can Be Discharged: Survey
April 2, 2001
- Sales of OTC Drugs in FY2000 Likely to Drop Due to Poor Prevalence of Flu
April 2, 2001
- Percentage of Deficit-ridden Hospitals Declines Slightly: NHFJ Survey
April 2, 2001
- Functional health food system to start april
April 2, 2001
- REGULATORY NEWS IN BRIEF
April 2, 2001
- COX-2 Inhibitors Show Effects against Cancer
April 2, 2001
- Korosho Urges Generic Makers to Ensure Stable Supply of Their Products
April 2, 2001
- Hp Eradication Saves 320 Bil. in Medical Expenses in 5 Years: Takeda Seminar
April 2, 2001
- BULLETIN
April 2, 2001
- Osteo Genesis Starts Developing Bone Regeneration Technology
April 2, 2001
- BUSINESS NEWS IN BRIEF
April 2, 2001
- MediBIC Licenses Haplotyping Technology from Genaissance
April 2, 2001
- Toho Transfers Business to Affiliated Companies to Increase Efficiency
April 2, 2001
- Sosei, Morphochem to Develop New Telomerase Inhibitor
April 2, 2001
- Industry FTC to Prohibit Financial Support for Social Gatherings at Medical Institutions
April 2, 2001
- Sankyo, Metabasis Agree to Continue Codevelopment of Antidiabetic Drug
April 2, 2001
- Sales of Relenza, Tamiflu Far Below Expectations
April 2, 2001
- Korosho to Start DRG Trial in April
April 2, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…